Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively

Journal of Cardiovascular Translational Research

Volumn 5, Issue 3, 2012, Pages 351-358

  Ibrahim, Michael ^a   El Hamamsy, Ismail ^a   Barbir, Mahmoud ^b   Yacoub, Magdi H ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Familial hypercholesterolaemia; Tolerance; Transplantation

Indexed keywords

ANTILIPEMIC AGENT; CREATININE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PREDNISOLONE; TRIACYLGLYCEROL; IMMUNOSUPPRESSIVE AGENT;

AORTA VALVE STENOSIS; ARTICLE; CARDIAC GRAFT REJECTION; CAROTID ARTERY BRUIT; CHOLESTEROL BLOOD LEVEL; COMBINED HEART AND LIVER TRANSPLANTATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ANALYSIS; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LOW DRUG DOSE; PRIORITY JOURNAL; XANTHOMA; ADULT; BLOOD; CASE REPORT; FEMALE; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; HYPERLIPOPROTEINEMIA TYPE 2; IMMUNOLOGY; MIDDLE AGED; MUTATION; TIME; TREATMENT OUTCOME;

ADULT; CHOLESTEROL, LDL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED; MUTATION; RECEPTORS, LDL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865837145     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-011-9311-1     Document Type: Article

References (43)

1. Soutar, A. K., & Naoumova, R. P. (2007). Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nature Clinical Practice. Cardiovascular Medicine, 4, 214-225. (Pubitemid 46502094)
2. Sibley, C., & Stone, N. J. (2006). Familial hypercholesterolemia: A challenge of diagnosis and therapy. Cleveland Clinic Journal of Medicine, 73, 57-64.
3. Allen, J. M., Thompson, G. R., Myant, N. B., Steiner, R., & Oakley, C. M. (1980). Cadiovascular complications of homozygous familial hypercholesterolaemia. British Heart Journal, 44, 361-368. (Pubitemid 11250363)
4. Lopez-Santamaria, M., Migliazza, L., Gamez, M., Murcia, J., Diaz-Gonzalez,M., Camarena, C., et al. (2000). Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass. Journal of Pediatric Surgery, 35, 630-633. (Pubitemid 30181048)
5. Thompsen, J., & Thompson, P. D. (2006). A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis, 189, 31-38. (Pubitemid 44444914)
6. Thompson, G. R., Barbir, M., Davies, D., Dobral, P., Gesinde, M., Livingston, M., et al. (2009). Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis, 208(2), 317-321.
7. Starzl, T. E., Bilheimer, D. W., Bahnson, H. T., Shaw, B. W., Jr., Hardesty, R. L., Griffith, B. P., et al. (1984). Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet, 1, 1382-1383. (Pubitemid 14122021)
8. Bilheimer, D. W., Goldstein, J. L., Grundy, S. M., Starzl, T. E., & Brown, M. S. (1984). Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. The New England Journal of Medicine, 311, 1658-1664. (Pubitemid 15183996)
9. Bilheimer, D. W. (1984). Regulation of LDL receptors in vivo. Agents and Actions. Supplements, 16, 191-203.
10. Brown, M. S., & Goldstein, J. L. (1974). Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proceedings of the National Academy of Sciences of the United States of America, 71, 788-792.
11. Brown, M. S., & Goldstein, J. L. (1976). Familial hypercholesterolemia: A genetic defect in the low-density lipoprotein receptor. The New England Journal of Medicine, 294, 1386-1390.
12. Poustie, V. J., & Rutherford, P. (2001). Dietary treatment for familial hypercholesterolaemia. Cochrane Database Syst Rev, 1, CD001918.
13. Schmidt, H. H., Tietge, U. J., Buettner, J., Barg-Hock, H., Offner, G., Schweitzer, S., et al. (2008). Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p. W577R LDL-receptor gene mutation. Clinical Transplantation, 22, 180-184. (Pubitemid 351420011)
14. Schmidt, H. H., Hill, S., Makariou, E. V., Feuerstein, I. M., Dugi, K. A., & Hoeg, J. M. (1996). Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. The American Journal of Cardiology, 77, 575-580. (Pubitemid 26113252)
15. Billingham, R. E., Brent, L., & Medawar, P. B. (1953). Actively acquired tolerance of foreign cells. Nature, 172, 603-606.
16. Shaw, B. W., Jr., Bahnson, H. T., Hardesty, R. L., Griffith, B. P., & Starzl, T. E. (1985). Combined transplantation of the heart and liver. Annals of Surgery, 202, 667-672. (Pubitemid 16229379)
17. Hoeg, J. M., Starzl, T. E., & Brewer, H. B., Jr. (1987). Liver transplantation for treatment of cardiovascular disease: Comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. The American Journal of Cardiology, 59, 705-707. (Pubitemid 17047346)
18. Valdivielso, P., Escolar, J. L., Cuervas-Mons, V., Pulpon, L. A., Chaparro, M. A., & Gonzalez-Santos, P. (1988). Lipids and lipoprotein changes after heart and liver transplantation in a patient with homozygous familial hypercholesterolemia. Annals of Internal Medicine, 108, 204-206. (Pubitemid 18081194)
19. Barbir, M., Khaghani, A., Kehely, A., Tan, K. C., Mitchell, A., Thompson, G. R., et al. (1992). Normal levels of lipoproteins including lipoprotein(a) after liver-heart transplantation in a patient with homozygous familial hypercholesterolaemia. The Quarterly Journal of Medicine, 85, 807-812. (Pubitemid 23012373)
20. Alkofer, B. J., Chiche, L., Khayat, A., Deshayes, J. P., Lepage, A., Saloux, E., et al. (2005). Liver transplant combined with heart transplant in severe heterozygous hypercholesterolemia: Report of the first case and review of the literature. Transplantation Proceedings, 37, 2250-2252. (Pubitemid 40956423)
21. Strober, S., Dhillon, M., Schubert, M., Holm, B., Engleman, E., Benike, C., et al. (1989). Acquired immune tolerance to cadaveric renal allografts: A study of three patients treated with total lymphoid irradiation. N Engl J Med, 321, 28-33. (Pubitemid 19170382)
22. Sayegh, M. H., Fine, N. A., Smith, J. L., Rennke, H. G., Milford, E. L., & Tilney, N. L. (1991). Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Annals of Internal Medicine, 114, 954-955.
23. Rana, A., Robles, S., Russo, M. J., Halazun, K. J., Woodland, D. C., Witkowski, P., et al. (2008). The combined organ effect: Protection against rejection? Annals of Surgery, 248, 871-879.
24. Mazariegos, G. V., Reyes, J., Marino, I. R., Demetris, A. J., Flynn, B., Irish, W., et al. (1997). Weaning of immunosuppression in liver transplant recipients. Transplantation, 63, 243-249. (Pubitemid 27121206)
25. Devlin, J., Doherty, D., Thomson, L., Wong, T., Donaldson, P., Portmann, B., et al. (1998). Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology, 27, 926-933. (Pubitemid 28160476)
26. Koshiba, T., Li, Y., Takemura, M., Wu, Y., Sakaguchi, S., Minato, N., et al. (2007). Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transplant Immunology, 17, 94-97. (Pubitemid 46240888)
27. Takatsuki, M., Uemoto, S., Inomata, Y., Sakamoto, S., Hayashi, M., Ueda, M., et al. (2001). Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance Transpl. Immunol., 8, 279-286. (Pubitemid 32249016)
28. Calne, R. Y. (1969). Strange english PIGS. Lancet, 2, 940-941.
29. Kamada, N., Brons, G., & Davies, H. S. (1980). Fully allogeneic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens. Transplantation, 29, 429-431. (Pubitemid 10037391)
30. Starzl, T. E., Demetris, A. J., Trucco, M., Ramos, H., Zeevi, A., Rudert, W. A., et al. (1992). Systemic chimerism in human female recipients of male livers. Lancet, 340, 876-877.
31. Starzl, T. E., Demetris, A. J., Murase, N., Ildstad, S., Ricordi, C., & Trucco, M. (1992). Cell migration, chimerism, and graft acceptance. Lancet, 339, 1579-1582.
32. Spitzer, T. R., Delmonico, F., Tolkoff-Rubin, N., McAfee, S., Sackstein, R., Saidman, S., et al. (1999). Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation, 68, 480-484. (Pubitemid 29416620)
33. Lubaroff, D. M., & Silvers, W. K. (1973). Importance of chimerism in maintaining tolerance of skin allografts in mice. Journal of Immunology, 111, 65-71.
34. Racanelli, V., & Rehermann, B. (2006). The liver as an immunological organ. Hepatology, 43, S54-S62.
35. Tiegs, G., & Lohse, A. W. (2009). Immune tolerance: What is unique about the liver. J Autoimmun, 34(1), 1-6.
36. English, K., French, A., & Wood, K. J. (2010). Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell, 7, 431-442.
37. Martinez-Llordella, M., Lozano, J. J., Puig-Pey, I., Orlando, G., Tisone, G., Lerut, J., et al. (2008). Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. The Journal of Clinical Investigation, 118, 2845-2857.
38. Yacoub, M. (2008). Heart transplantation: The end of the beginning. American Journal of Transplantation, 8, 1767-1768.
39. Hamour, I. M., Omar, F., Lyster, H. S., Palmer, A., & Banner, N. R. (2009). Chronic kidney disease after heart transplantation. Nephrology, Dialysis, Transplantation, 24, 1655-1662.
40. Lyster, H., Leaver, N., Hamour, I., Palmer, A., & Banner, N. R. (2009). Transfer from ciclosporin to mycophenolate-sirolimus immunosuppression for chronic renal disease after heart transplantation: safety and efficacy of two regimens. Nephrology, Dialysis, Transplantation, 24, 3872-3875.
41. Lee, J. H., Lee, S. K., Lee, H. J., Seo, J. M., Joh, J. W., Kim, S. J., et al. (2009). Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Medical Journal, 50, 784-788.
42. Benitez, C., Lozano, J. J., & Fueyo, A. S. (2009). Gene expression profiling and transplantation tolerance in the clinic. Transplantation, 88, S50-S53.
43. Rajamannan, N. M., Edwards, W. D., & Spelsberg, T. C. (2003). Hypercholesterolemic aortic-valve disease. The New England Journal of Medicine, 349(7), 717-718. doi:10.1056/NEJMc031360